| __timestamp | Eli Lilly and Company | Gilead Sciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 2983000000 |
| Thursday, January 1, 2015 | 6533000000 | 3426000000 |
| Friday, January 1, 2016 | 6452000000 | 3398000000 |
| Sunday, January 1, 2017 | 6588100000 | 3878000000 |
| Monday, January 1, 2018 | 5975100000 | 4056000000 |
| Tuesday, January 1, 2019 | 6213800000 | 4381000000 |
| Wednesday, January 1, 2020 | 6121200000 | 5151000000 |
| Friday, January 1, 2021 | 6431600000 | 5246000000 |
| Saturday, January 1, 2022 | 6440400000 | 5673000000 |
| Sunday, January 1, 2023 | 6941200000 | 6090000000 |
| Monday, January 1, 2024 | 8593800000 | 6091000000 |
Unlocking the unknown
In the competitive pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Eli Lilly and Gilead Sciences have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking at approximately $6.94 billion in 2023. In contrast, Gilead Sciences started with lower SG&A costs, around $2.98 billion in 2014, but experienced a significant rise, reaching $6.09 billion by 2023.
Eli Lilly's expenses grew by about 5% over the period, while Gilead's surged by over 100%. This stark difference highlights Eli Lilly's more consistent cost management strategy compared to Gilead's rapid expansion. As investors and industry analysts evaluate these trends, understanding the implications of SG&A expenses on overall financial health becomes paramount.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Comparing SG&A Expenses: Novartis AG vs Gilead Sciences, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and Vertex Pharmaceuticals Incorporated
Gilead Sciences, Inc. vs Alnylam Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Regeneron Pharmaceuticals, Inc.
Gilead Sciences, Inc. vs Rhythm Pharmaceuticals, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Gilead Sciences, Inc. and CRISPR Therapeutics AG
Comparing SG&A Expenses: Gilead Sciences, Inc. vs Galapagos NV Trends and Insights
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs BioCryst Pharmaceuticals, Inc.